Prescription opioid abuse is becoming an increasingly widespread and serious public health concern. The 2001 National Household Survey on Drug Abuse report revealed that the number of first-time users of prescription opioid medications for non-medical reasons reached 2.0 million in the year 2000, a number that has quintupled since 1984, and the 2002 Drug Abuse Warning Network (DAWN) report showed that the number of emergency department mentions of several prescription opioid medications more than doubled between 1994 and 2001. Despite these trends, little experimental research has been directed towards understanding who may be abusing these medications, and under what conditions. The current application will examine the reinforcing, subjective, performance, and physiological effects of two commonly prescribed opioid medications (oxycodone, codeine) in two separate studies. Because it is not clear who is abusing prescription opioids, the medication effects will be compared in drug abusers and non-drug abusers. And because it is not clear under what conditions these medications are used, the effects of oxycodone and codeine will be examined in the presence and absence of experimentally-induced pain. For each study, one between- [drug use history (drug abusers, non-drug abusers)] and two within-subjects variables [pain condition (pain, no pain); medication dose (placebo, low, high dose)] will be examined. Because previous studies have shown sex differences in response to opioid medications, we will attempt to enroll equivalent numbers of men and women in each study so that we can conduct exploratory analyses of sex differences in response to oxycodone and codeine. The results of these studies will yield important information about who may be abusing prescription opioid medications, and will provide a better understanding of several important variables that may influence the propensity to abuse these medications.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA016759-05
Application #
7237855
Study Section
Special Emphasis Panel (ZRG1-BBBP-2 (02))
Program Officer
Montoya, Ivan
Project Start
2003-09-20
Project End
2009-05-31
Budget Start
2007-06-01
Budget End
2009-05-31
Support Year
5
Fiscal Year
2007
Total Cost
$414,936
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Jones, Jermaine D; Campbell, Aimee; Metz, Verena E et al. (2017) No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addict Behav 71:104-106
Jones, Jermaine D; Luba, Rachel R; Vogelman, Jonathan L et al. (2016) Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. Am J Addict 25:41-8
Askalsky, Paula; Kalapatapu, Raj K; Foltin, Richard W et al. (2015) Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users. Am J Drug Alcohol Abuse 41:161-5
Jones, Jermaine D; Comer, Sandra D (2015) A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend 152:1-14
Jones, Jermaine D; Comer, Sandra D; Kranzler, Henry R (2015) The pharmacogenetics of alcohol use disorder. Alcohol Clin Exp Res 39:391-402
Greenwald, Mark K; Comer, Sandra D; Fiellin, David A (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 144:1-11
Jones, Jermaine D; Madera, Gabriela; Comer, Sandra D (2014) The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. Pharmacol Biochem Behav 122:299-306
Smith, Shannon M; Dart, Richard C; Katz, Nathaniel P et al. (2013) Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain 154:2287-96
Vosburg, Suzanne K; Jones, Jermaine D; Manubay, Jeanne M et al. (2013) A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction 108:1095-106
Comer, Sandra D; Metz, Verena E; Cooper, Ziva D et al. (2013) Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behav Pharmacol 24:504-16

Showing the most recent 10 out of 24 publications